Coronavirus studies
Numerous coronavirus studies demonstrate the prophylactic and early use effectiveness of hydroxychloroquine (HCQ) against COVID-19, which are being ignored or downplayed for political reasons.
Here is a sampling of the growing list of valid studies confirming the effectiveness of hydroxychloroquine against COVID-19:
Compilation
A compilation of coronavirus studies demonstrates the effectiveness of early treatment by hydroxychloroquine.[1]
Saudi Arabia
An observational prospective cohort study examined in 238 ambulatory fever clinics in Saudi Arabia, based on the Ministry of Health (MOH) COVID-19 treatment guidelines.
The comparison was between 1,817 patients in the HCQ group vs 3,724 in the merely supportive care ("SC") group.
The results were as follows:
| “ | Early HCQ-based therapy was associated with a lower hospital admission within 28-days compared to SC alone (9.4% compared to 16.6%, RRR 43%, p-value <0.001). The composite outcome of ICU admission and/or mortality at 28-days was also lower in the HCQ group compared to the SC (1.2% compared to 2.6%, RRR 54%, p-value 0.001). Adjusting for age, gender, and major comorbid conditions, a multivariate logistic regression model showed a decrease in the odds of hospitalisation in patients who received HCQ compared to SC alone (adjusted OR 0.57 [95% CI 0.47-0.69], p-value <0.001). The composite outcome of ICU admission and/or mortality was also lower for the HCQ group compared to the SC group controlling for potential confounders (adjusted OR 0.55 [95% CI 0.34-0.91], p-value 0.019). CONCLUSION: Early intervention with HCQ-based therapy in patients with mild to moderate symptoms at presentation is associated with lower adverse clinical outcomes among COVID-19 patients, including hospital admissions, ICU admission, and/or death.[2] | ” |
Greek study suggests why HCQ is effective
A small Greek study indicates that HCQ is effective because it inhibits a hyperinflammatory reaction progression, if given in early stages of the disease.[3]
Minnesota data mining study
The incidence rate and mortality from COVID-19 was found to be lower in patients on chronic hydroxychloroquine therapy, in a large Minnesota healthcare system.
Between April 1, 2019 and March 31, 2020, the database contained 1,271,014 unique patient encounters, including a total of 2945 COVID-19 tests, of which 125 (4.24%) were positive.
Among the tests performed, 124 (4.35%) were positive for COVID-19 while not having taken hydroxychloroquine, while 96 tests were performed in patients with existing hydroxychloroquine prescriptions and only one (1.04%) was positive.
Two COVID-19 patients not on hydroxychloroquine died, while no COVID-19 patients not on hydroxychloroquine died.
Hydroxychloroquine appears to be effective against COVID-19 both as a prophylaxis and as early treatment.[4]
French study
In a study of 3,737 COVID-19 patients, the researchers found that "Treatment with HCQ-AZ was associated with a decreased risk of transfer to ICU or death (Hazard ratio (HR) 0.18 0.11–0.27), decreased risk of hospitalization ≥10 days and shorter duration of viral shedding."[5]